Palau de Congressos de Catalunya
2018, October 24-27
The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2017 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2018 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.